Heart Rhythm Daily - Day 2, 2008 - (Page 1)

D A I LY HIGHLIGHTS M AY 1 6 , 2 0 0 8 Friday, May 16 2 L AT E - B R E A K I N G C L I N I C A L T R I A L S 6:00 – 7:45 a.m. . . . . . . . Approved Satellite Symposia 7:30 a.m. – 7:00 p.m. . . . . . . . . . . . . . Registration Open 8:00 - 9:30 a.m. . . . . . . . . . . . . . . . . . . Scientiﬁc Sessions 8:00 - 9:30 a.m. . . . . . . . . . . . . .Live Case Presentations 9:00 a.m. – 5:00 p.m. . . . . . . . . . . . . . Exhibit Hall Open 10:30 a.m. - 12:30 p.m. . . . . . . . . . . Scientiﬁc Sessions 10:30 a.m. - 12:30 p.m. . . . . . . . . . .Young Investigator Awards Competition 12:15 - 1:15 p.m. . . . .Experts Unplugged Luncheons 12:15 - 1:15 p.m. . . . . . .Meet-the-Experts Luncheons 12:15 - 1:15 p.m. . . . .Fellowship Directors Luncheon 1:30 - 3:00 p.m. . . . . . . . . . . . . . . . . . . Scientiﬁc Sessions 1:30 - 3:00 p.m. . . . . . . . . . . . . .Live Case Presentations 4:30– 6:00 p.m. . . . . . . . . . . . . . . . . . . Scientiﬁc Sessions 6:30 – 7:30 p.m. . . . . . . . . . . . . . .President’s Reception New research explores various therapies for cardiac arrhythmias YESTERDAY’S LATE-BREAKING CLINICAL therapy with targeted left-ventricular (LV) Trials session presented the results of six tri- lead placement versus CRT with usual lead als evaluating a variety of therapies for car- placement for 96 heart-failure patients. diac arrhythmias, including antiarrhythDr. Exner deﬁned the primary outcome of mic drug therapy, cardiac resynchroniza- the study as survival for at least six months, tion therapy (CRT), biventricular (BiV) pac- a one New York Heart Association (NYHA) ing, and remote interrogation for implant- class or larger reduction in symptoms, able cardioverter deﬁbrillator (ICD) therapy. and at least a 10 percent reduction in LV Stefan H. Hohnloser, MD, FHRS, from end-systolic volume as evaluated by SPECT the J.W. Goethe University in Frankfurt, MUGA imaging. Germany, reported the reTargeted lead placement sults of the ATHENA trial, involved LV pacing from the a placebo-controlled trial latest site of mechanical acdesigned to assess the eftivity. The study found that ficacy of dronedarone, a targeted placement results new antiarrhythmic drug in a higher rate of response for atrial fibrillation (AF) to CRT in patients with ischand atrial ﬂutter (AFl), in emic LV dysfunction, but the prevention of cardiothere was no apparent benvascular hospitalization eﬁt in patients with nonor death. ischemic LV dysfunction. More than 4,600 patients Stefan H. Hohnloser, MD, FHRS A study of the value of with AF or AFl or a history giv ing antiarrhy thmic of AF or AFl received 400 mg dronedarone drugs for six months after ablation therapy bid or placebo and were followed for up to to patients with paroxysmal AF, the 5A 30 months. The study found a signiﬁcant 24 Study, was reported by Jean-Francois Roux, percent reduction in the primary endpoint MD, from the Hospital of the University of of cardiovascular hospitalization or death Pennsylvania, Philadelphia. from all causes (but primarily hospitalizaThe primary endpoint was a composite tion) and a 30 percent reduction in cardio- of clinically signiﬁcant atrial arrhythmias vascular death with dronedarone use. for more than 24 hours or severe sympDerek V. Exner, MD, MPH, from the Libin toms requiring therapy. Dr. Roux and his Cardiovascular Institute of Alberta in Cal- colleagues concluded that treating their gary, Canada, described the INCREMENTAL 101 patients with antiarrhythmics after study, a randomized comparison of CRT ablation reduced the incidence of signiﬁcant atrial arrhythmias and the need for cardioversion or hospitalization. The ADVANCE CRT-D trial compared the safety and efficacy of BiV ICD antitachycardia pacing versus conventional right-ventricular (RV) pacing to terminate ventricular tachyarrhythmias in patients receiving CRT, according to Maurizio Gasparini, MD, from the Instituto Clinico Humanitas in Milan, Italy, who presented the study. Among the 526 patients randomized to the two forms of pacing, the study found no significant difference in efficacy between BiV pacing and RV pacing and that RV pacing was signiﬁcantly less effective in ischemic patients than in non-ischemic patients. BiV pacing appears to have a superior safety proﬁle. Michael R. Gold, MD, PhD, from the Medical University of South Carolina in Charleston, reported the results of the REVERSE trial of the effect of CRT on the incidence of spontaneous ventricular arrhythmias in 610 patients with mild (NYHA class I or II) heart failure who underwent implantation of a CRT system with or without ICD capabilities. Dr. Gold and his colleagues randomized the patients to receive either CRT with optimal medical therapy or optimal medical therapy alone to see if CRT could attenuate the progression of heart failure and help decrease the incidence of ventricular See Clinical Trials, page 3 INSIDE Town Hall Meetings . . . . . . . . . . 3 Society leaders tackled key issues affecting the profession during Wednesday’s Town Hall Meetings. Live Cases . . . . . . . . . . . . . . . . . . . 8 Experts from two premiere facilities will demonstrate multiple procedures during a live presentation today. Board Review . . . . . . . . . . . . . . . 10 Courses offer opportunity to complete American Board of Internal Medicine modules for clinical cardiac EP. VT/VF Summit reviews latest information for diagnosis, treatment On Wednesday, William Stevenson, MD, FHRS (pictured), and SCA 360° Chair John DiMarco, MD, PhD, FHRS, led the VT/VF Summit, which brought together world-renowned experts to share the latest developments in the recognition and management of patients at risk for sudden cardiac arrest. The summit included lectures on such topics as new drug therapy, genetic research, appropriate use of device therapy, and the epidemiology of sudden cardiac arrest. The summit also included presentations of advanced therapeutic procedures. “These are things that don’t come up frequently in most laboratories,” Dr. DiMarco said. “You could go to 100 meetings and never receive this extensive information.” The summit marked the official kick-off of the Heart Rhythm Society’s SCA 360° initiative, a multi-year project aimed at reducing mortality from sudden cardiac arrest.

Table of Contents Feed for the Digital Edition of Heart Rhythm Daily - Day 2, 2008

Contents Town Hall Meetings Live Cases Board Review

Heart Rhythm Daily - Day 2, 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.